Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrás AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, Jänne PA. Engelman JA, et al. Among authors: zejnullahu k. J Clin Invest. 2006 Oct;116(10):2695-706. doi: 10.1172/JCI28656. Epub 2006 Aug 10. J Clin Invest. 2006. PMID: 16906227 Free PMC article.
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA. Engelman JA, et al. Among authors: zejnullahu k. Science. 2007 May 18;316(5827):1039-43. doi: 10.1126/science.1141478. Epub 2007 Apr 26. Science. 2007. PMID: 17463250
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.
Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Jänne PA. Engelman JA, et al. Among authors: zejnullahu k. Cancer Res. 2007 Dec 15;67(24):11924-32. doi: 10.1158/0008-5472.CAN-07-1885. Cancer Res. 2007. PMID: 18089823
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor.
Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, Lifshits E, Brown A, Lee C, Christensen JG, Kwiatkowski DJ, Engelman JA, Jänne PA. Ercan D, et al. Among authors: zejnullahu k. Oncogene. 2010 Apr 22;29(16):2346-56. doi: 10.1038/onc.2009.526. Epub 2010 Feb 1. Oncogene. 2010. PMID: 20118985 Free PMC article.
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee C, Meyerson M, Jänne PA. Koivunen JP, et al. Among authors: zejnullahu k. Clin Cancer Res. 2008 Jul 1;14(13):4275-83. doi: 10.1158/1078-0432.CCR-08-0168. Clin Cancer Res. 2008. PMID: 18594010 Free PMC article.
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.
Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Jänne PA. Turke AB, et al. Among authors: zejnullahu k. Cancer Cell. 2010 Jan 19;17(1):77-88. doi: 10.1016/j.ccr.2009.11.022. Cancer Cell. 2010. PMID: 20129249 Free PMC article.
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.
Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, Fujisaka Y, Philips J, Shimizu T, Maenishi O, Cho Y, Sun J, Destro A, Taira K, Takeda K, Okabe T, Swanson J, Itoh H, Takada M, Lifshits E, Okuno K, Engelman JA, Shivdasani RA, Nishio K, Fukuoka M, Varella-Garcia M, Nakagawa K, Jänne PA. Yonesaka K, et al. Among authors: zejnullahu k. Sci Transl Med. 2011 Sep 7;3(99):99ra86. doi: 10.1126/scitranslmed.3002442. Sci Transl Med. 2011. PMID: 21900593 Free PMC article.
16 results